Skip to Content
Merck
  • Pulsatile systems for colon targeting of budesonide: in vitro and in vivo evaluation.

Pulsatile systems for colon targeting of budesonide: in vitro and in vivo evaluation.

Drug delivery (2011-11-25)
Soad A Yehia, Ahmed H Elshafeey, Ibrahim Elsayed
ABSTRACT

The purpose of this study is to increase the lag time and prevent release of budesonide, a corticosteroid drug used in Crohn's disease for the first 5 h and efficiently deliver it to the colon. Eudragit S100 spray-coated capsules and pulsatile systems using tablet plugs of cellulose acetate butyrate (CAB), HPMC K4M, guar gum, and pectin were prepared. Eudragit S100-coated capsules released 80.62% after 5 h. In pulsatile systems, decreasing the ratio of the polymer significantly increased the rate and extent of drug release. Spray-coating with EUD S100 decreased the extent of drug release to 48.41%, 69.94%, 80.58%, and 45.23% in CAB, HPMC K4M, pectin, and guar gum, respectively; however, the entire amount was released in the target area. In the presence of bacterial enzymes, selected formulas showed nearly 100% release. X-ray imaging performed to monitor the capsules throughout the GIT in human volunteers of the capsules and spray-coated pulsatile systems with 25% guar gum in the plug showed bursting in the transverse and ascending colon, respectively. Both formulations showed marked reduction in induced rabbit colitis model.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cellulose acetate butyrate, average Mn ~12,000
Sigma-Aldrich
Cellulose acetate butyrate, average Mn ~70,000
Sigma-Aldrich
Cellulose acetate butyrate, average Mn ~30,000
Sigma-Aldrich
Cellulose acetate butyrate, average Mn ~30,000
Sigma-Aldrich
Cellulose acetate butyrate